EUVIMEDObjevte EUVIMED
Crossref

Evaluation of sitagliptin therapy on the levels of fibroblast growth factor-19 (FGF19) in patients with Type 2 diabetes

Özen ÖZ GÜL, Soner CANDER

Turkish Journal of Internal Medicine · 2022

DOI: 10.46310/tjim.1070223 ↗

At a glance

Journal article in Turkish Journal of Internal Medicine, 2022. Written by Özen ÖZ GÜL and 1 co-authors. 16 references.

AbstraktBibliografické údajeCiteRelated studies

Abstract (original language)

Introduction

The specific association between sitagliptin and Fibroblast Growth Factor-19 (FGF19) is yet to be clarified. In this study, we aimed to investigate the effect of sitagliptin therapy on the levels of FDF19 in patients with type 2 diabetes mellitus (T2DM).

Methods

A total of 35 patients newly diagnosed type 2 diabetes, and who had not received antidiabetic treatment before were included in this study. Sitagliptin therapy was administered as 100 mg/day. Patients’ demographic, anthropometric features, glycaemic variables, lipid profiles and FGF19 values were evaluated at the baseline and at the 3rd month of the treatment and the obtained data were compared.

Results

The mean age of the patients was 53.34 ± 8.09 years. The mean weight, body mass index (BMI), hip circumference, postprandial blood glucose and glycosylated haemoglobin A1c (HbA1c) values were statistically significantly lower at the 3rd month of the treatment compared to the baseline values (for all, p

Cite

APA

GÜL, Ö. Ö., & CANDER, S. (2022). Evaluation of sitagliptin therapy on the levels of fibroblast growth factor-19 (FGF19) in patients with Type 2 diabetes. Turkish Journal of Internal Medicine. https://doi.org/10.46310/tjim.1070223

Vancouver

GÜL ÖÖ, CANDER S. Evaluation of sitagliptin therapy on the levels of fibroblast growth factor-19 (FGF19) in patients with Type 2 diabetes. Turkish Journal of Internal Medicine. 2022. doi:10.46310/tjim.1070223

BibTeX
@article{GL2022,
  author = {GÜL, Özen ÖZ and CANDER, Soner},
  title = {Evaluation of sitagliptin therapy on the levels of fibroblast growth factor-19 (FGF19) in patients with Type 2 diabetes},
  journal = {Turkish Journal of Internal Medicine},
  year = {2022},
  doi = {10.46310/tjim.1070223}
}
Start for free →